SP Group (SPG) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
26 Dec, 2025Executive summary
Achieved record revenue of DKK 2.922 billion in 2024, up 12.1% year-over-year, driven by strong growth in own products and strategic focus on key sectors.
Own products now account for 30% of revenue, supporting margin improvements and global expansion.
Opened a new U.S. factory, expanding injection molding capacity and reducing tariff risks.
Closed underperforming facilities in Denmark, including Neptune Plastic and Kvistgård, to optimize operations.
Strategic initiatives include acquisitions, sustainability, and increasing the share of own products.
Financial highlights
Q4 2024 revenue: DKK 727 million (+11.3%); full-year revenue: DKK 2.922 billion (+12.1%).
EBITDA for 2024: DKK 599 million (+34%); EBIT: DKK 386 million (+60%); EBT: DKK 345 million (+71.5%).
Earnings per share rose to DKK 21.6 from DKK 13; equity increased 16% to DKK 1.7 billion.
Net interest-bearing debt reduced to DKK 821 million; debt/EBITDA at 1.4; equity ratio nearly 54%.
Share return in 2024 was 45%; proposed dividend of DKK 4 per share (19.1% payout ratio).
Outlook and guidance
2025 revenue growth expected at 3%-10%, with EBITDA margin of 19%-21% and EBIT/EBT margin of 11%-13%.
Long-term ambition for 2030: DKK 4.5 billion revenue, DKK 600 million EBIT/EBT, 6%-9% annual growth.
Continued focus on organic growth, own product expansion, and selective acquisitions.
Latest events from SP Group
- Strong H1 2024 growth, upgraded outlook, and international expansion led by healthcare sales.SPG
Q2 202423 Jan 2026 - Acquisition enables in-house toolmaking, new materials, and DKK 20–25m annual synergies.SPG
M&A Announcement19 Dec 2025 - Record Q1 growth and margin gains led by Healthcare; outlook steady amid global risks.SPG
Q1 202524 Nov 2025 - Q2 slowdown led to lower H1 results and a flat outlook, but margins and investments remain strong.SPG
Q2 202523 Nov 2025 - 2025 guidance maintained as order backlog and new projects offset lower sales and margins.SPG
Q3 202520 Nov 2025 - Revenue down 3.3% in 9M 2025, but guidance and growth outlook remain stable.SPG
Q3 202520 Nov 2025 - H1 2025 saw revenue and earnings decline, but margin guidance and growth projects remain on track.SPG
Q2 202520 Aug 2025 - Strong own-brand and healthcare sales drove double-digit profit and margin growth in 2024.SPG
Q3 202413 Jun 2025 - Record Q1 growth and margin expansion, with 2025 outlook unchanged.SPG
Q1 20256 Jun 2025